In this episode of the Life Science Success Podcast, host Don interviews Sean Rothwell, CEO of Evoke Nano, about the company's groundbreaking work in developing EBQ218, a revolutionary nanoparticle-based pulmonary therapeutic. They discuss the efficacy of EBQ218 in treating cystic fibrosis and its potential as a broad-spectrum antibiotic against drug-resistant superbugs. Sean shares insights into the company's journey, their upcoming clinical trials, and the broader impact of their work on patient outcomes in the healthcare landscape. Tune in to learn how Evoke Bio is poised to make a significant difference in combating infectious diseases and improving lives.
00:00 Welcome and Introduction
00:09 First Impressions of BIO Conference
00:37 Sean's Background and Journey into Life Sciences
01:42 The Science Behind Evoke Nano
02:28 EBQ218: A Revolutionary Pulmonary Therapeutic
04:16 Challenges and Future Pathways
05:24 Investment and Partnership Opportunities
06:42 Broader Applications and Future Vision
08:16 Addressing Drug Resistance and Regulatory Pathways
18:48 Conclusion and Final Thoughts
Please check out our Life Science Success Resources. You will find tools that will support growing companies and books for authors I have interviewed.